Introduction
The last few years have witnessed something of a renaissance in the field of cancer immunotherapy, relating largely to the clinical advances that have been associated with the development of monoclonal antibodies (mAbs) targeting the immune inhibitory coreceptors, such as CTLA-4. Subversion of these inhibitory checkpoints is a powerful mechanism by which tumors could evade host immune responses. Therapeutic advances are based on a more substantial understanding of the factors and regulatory cells restricting effective immune therapies that have been derived from the study of preclinical models of tumor initiation, growth, and metastasis in immunecompetent mice.
1,2 Now, anti-CTLA-4 mAbs have been shown to prolong overall survival in patients with advanced melanoma. 3, 4 CTLA-4 is the archetypal immune regulatory checkpoint. CTLA-4 is expressed exclusively on T cells, and its ligands CD80 (B7.1) and CD86 (B7.2) are restricted largely to professional antigenpresenting cells, such as dendritic cells and monocytes. Functionally, anti-CTLA-4 primarily counteracts the costimulatory activity of CD28, which shares the same two ligands. The precise mechanisms underpinning the enhanced antitumor immunity demonstrated with anti-CTLA-4 antibodies remain somewhat controversial. In addition to its direct cell intrinsic function in dampening effector T cell (Teff) responses, CTLA-4 is highly expressed on regulatory T cells (Tregs). The engagement of the receptors on Tregs appears critical for maximal antitumor activity by anti-CTLA-4 mAbs.
5
Many possible combinatorial strategies based on ipilimumab and/or Treg are being investigated in preclinical models or in the clinic. 6 One interesting possibility is to combine anti-CTLA-4 with an agent that blocks another inhibitory molecule on Treg, such as receptor activator of NF-kB (RANK) ligand (RANKL). RANK signaling controls osteoclastogenesis and bone resorption and has been targeted to prevent bone metastasis in breast and prostate cancers. A humanized anti-RANKL antibody (denosumab) appears to be a more effective inhibitor of bone metastasis than other osteoclast-targeting drugs. 7, 8 Recently, RANKL expression on Treg has been shown to engage the RANK receptor on cancer cells and to promote metastasis. 9 Inhibitors of RANK signaling, such as anti-RANKL antibody denosumab, already used against osteoclast-mediated bone resorption, may block direct Treg-induced metastases of certain cancers.
We describe a case of rapidly advancing metastatic melanoma with aggressive and symptomatic bone metastases requiring treatment with the anti-RANKL antibody denosumab for palliation, in a patient who was concomitantly treated with the anti-CTLA4 antibody ipilimumab.
Case Report
A 39-year-old woman with a history of a 0.8-mm, BRAF wild type, nonulcerated melanoma with an elevated mitotic count at 1 
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, arising from the back, presented 13 months after initial diagnosis with an axillary nodal mass and widespread bone metastases ( Fig 1A) with a serum LDH of Ͼ 10 times the upper limit of normal and an Eastern Cooperative Oncology Group performance status of 2. She required opiate analgesia, celecoxib, pregabalin, and urgent palliative radiotherapy for painful rib metastases. She was commenced on denosumab 120 mg once every 4 weeks for widespread severe bone pain that limited her mobility. The patient received a single dose of dacarbazine 850 mg/m 2 for treatment of the melanoma. However as a result of performance status deteriorating to ECOG 3, poorly controlled bone pain, and the emergence of a leukoerythroblastic blood film with anemia and thrombocytopenia (Hb 99 g/dL, platelets 138 ϫ 10 9 /L, and circulating blasts and nucleated RBCs) dacarbazine was ceased, and the patient was treated with ipilimumab 3 mg/kg. The patient's pain improved dramatically over the next 3 weeks; however, she became progressively more anemic, with a worsening leukoerythroblastic blood film that required RBC transfusion. By the completion of a total of four doses of ipilimumab given every 3 weeks, the patient's pain had completely resolved, LDH normalized, and hematology returned to normal. She did not develop any immune-related toxicities. Denosumab continued to be delivered every 4 weeks. Fluorodeoxyglucosepositron emission tomography (FDG-PET) scan performed 16 weeks after the first dose of ipilimumab and 18 weeks after the first dose of denosumab showed a dramatic partial response (Fig 1) . Subsequently, the patient underwent repeat FDG-PET scan 2 months later that revealed persisting disease in a single focus in the humerus and lymph node metastases in single axillary nodal basin (Fig 1) . She proceeded to lymphadenectomy and radiotherapy to the humerus. She remained free of disease progression until 48 weeks after commencing ipilimumab, when she developed a single cerebral metastasis that was resected. A second cerebral metastasis also developed at week 62 and was successfully treated with stereotactic radiotherapy. There was no evidence of any residual melanoma on FDG-PET scan at this time.
Discussion and Preclinical Evaluation of the Combination of Anti-CTLA4 and Anti-RANKL
Using the B16F10 melanoma preclinical model of experimental metastases, we have now demonstrated that anti-CTLA-4 (UC10-4F10, 100 g intraperitoneal on days Ϫ1, 0, and 2) and anti-RANKL (IK22-5, 200 g on days Ϫ1, 0, and 2) mAbs have modest antimetastatic activities alone, but considerably enhanced metastases suppression when combined together at the time of intravenous melanoma inoculation (Fig 2A) . Similar data were obtained when using a B16 variant that expressed the foreign OVA antigen, in an identical metastases assay (data not shown). In addition, combinatorial benefit was observed in mice bearing established subcutaneous B16F10 (treatment commencing on day 6), or SM1WT1-OVA (treatment commencing on day 12) melanomas, compared with anti-CTLA-4 or anti-RANKL alone (data not shown). The combination effect of anti-CTLA-4 and anti-RANKL was dependent on lymphocytes, as treatment was completely ineffective in RAG2Ϫ/Ϫ␥cϪ/Ϫ mice lacking all lymphocytes (Fig 2B) . Combined treatment was also largely ineffective in mice specifically depleted of natural killer cells using antiasialoGM1, but still largely effective in mice depleted of T cells using anti-CD4 (GK.15) and anti-CD8␤ (53.5.8) mAbs. These data indicated that a combination of natural killer cells and T cells were responsible for the antitumor activity of anti-CTLA-4 and anti-RANKL mAbs. Interestingly, the level of metastases suppression caused by this combination was not as great as seen under identical experimental conditions where Tregs were conditionally and completely depleted ( Figure S4 Smyth, Yagita, and McArthur
